Intellia Therapeutics (NASDAQ:NTLA) Price Target Lowered to $20.00 at The Goldman Sachs Group

Intellia Therapeutics (NASDAQ:NTLA) had its price objective decreased by The Goldman Sachs Group from $31.00 to $20.00 in a research report released on Friday, Benzinga reports. The Goldman Sachs Group currently has a neutral rating on the stock.

Other equities analysts also recently issued research reports about the stock. StockNews.com upgraded shares of Intellia Therapeutics to a “sell” rating in a research note on Thursday, June 27th. JPMorgan Chase & Co. cut their price objective on shares of Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating for the company in a research report on Monday, August 12th. Canaccord Genuity Group restated a “buy” rating and issued a $73.00 price objective on shares of Intellia Therapeutics in a research report on Thursday, June 27th. Evercore ISI upgraded shares of Intellia Therapeutics to a “strong-buy” rating in a research report on Friday, August 9th. Finally, Chardan Capital dropped their target price on shares of Intellia Therapeutics from $94.00 to $88.00 and set a “buy” rating for the company in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $59.13.

Intellia Therapeutics Stock Up 0.6 %

NASDAQ NTLA traded up $0.10 during trading hours on Friday, reaching $15.95. 3,768,009 shares of the company were exchanged, compared to its average volume of 1,600,623. Intellia Therapeutics has a 1 year low of $15.35 and a 1 year high of $34.87. The business’s 50 day simple moving average is $20.71 and its 200-day simple moving average is $22.75. The stock has a market capitalization of $1.62 billion, a P/E ratio of -2.91 and a beta of 1.76.

Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Thursday, August 8th. The company reported ($1.52) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.29). The firm had revenue of $7.00 million for the quarter, compared to analysts’ expectations of $19.68 million. The firm’s quarterly revenue was down 48.5% on a year-over-year basis. During the same period last year, the firm earned ($1.40) EPS. As a group, sell-side analysts anticipate that Intellia Therapeutics will post -5.22 earnings per share for the current year.

Insider Activity

In other news, CAO Michael P. Dube sold 2,012 shares of the business’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total transaction of $38,248.12. Following the sale, the chief accounting officer now owns 47,012 shares in the company, valued at approximately $893,698.12. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 3.20% of the company’s stock.

Hedge Funds Weigh In On Intellia Therapeutics

Hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in Intellia Therapeutics by 1.9% during the 4th quarter. Vanguard Group Inc. now owns 8,347,449 shares of the company’s stock valued at $254,514,000 after acquiring an additional 155,579 shares during the period. PNC Financial Services Group Inc. lifted its stake in Intellia Therapeutics by 209.7% during the 4th quarter. PNC Financial Services Group Inc. now owns 10,561 shares of the company’s stock valued at $322,000 after acquiring an additional 7,151 shares during the period. SteelPeak Wealth LLC bought a new position in Intellia Therapeutics during the 1st quarter valued at about $229,000. Allspring Global Investments Holdings LLC lifted its stake in Intellia Therapeutics by 9.2% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 8,894 shares of the company’s stock valued at $245,000 after acquiring an additional 750 shares during the period. Finally, Commonwealth Equity Services LLC lifted its stake in Intellia Therapeutics by 6.2% during the 1st quarter. Commonwealth Equity Services LLC now owns 34,593 shares of the company’s stock valued at $952,000 after acquiring an additional 2,034 shares during the period. Institutional investors own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.